Viridian Therapeutics, Inc. nears profitability and gears up for veligrotug’s 2025 launch. Click here to find out why VRDN ...

Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

IgE, best known for mediating allergic reactions, may also shape cancer outcomes. Learn how this immune molecule could serve ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent variations with clear ...

Scientists have built an AI-powered clock called gtAge that reads your blood to reveal your true biological age.

Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, spoke with Healio about “clear-cut indicators” to differentiate between different types of autoimmune biliary diseases. He ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL ...